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Targeting alpha-synuclein (α-syn) as a therapeutic strategy for Parkinson’s disease (PD) has been intensively pursued
largely due to its well-recognized pathogenic role. Since its discovery as the first familial link to PD over two decades
ago, this protein has been associated with multiple neurotoxic mechanisms, such as mitochondrial dysfunction and
impaired autophagic flux. We report here that blocking dynamin-related protein 1 (Drp1) improved both mitochondrial
function and autophagic flux in experimental models of α-syn. Using rat dopaminergic neuronal cells with inducible
wild-type human α-syn, we observed excessive mitochondrial fragmentation and increased Drp1 levels 48 h after gene
induction. Functionally, these cells exhibited lower mitochondrial membrane potential, reduced ATP production rate
and mitochondrial spare respiratory capacity, as well as increased levels of mitochondrial reactive oxygen species. To
evaluate the protective role of Drp1 inhibition, we used three complementary approaches: gene silencing mediated by
siRNA, overexpression of Drp1-dominant negative and the small molecule mitochondrial division inhibitor-1 (mdivi-1).
Both morphological and functional defects induced by α-syn were attenuated by these strategies. Importantly, Drp1
inhibition reduced proteinase K-resistant α-syn aggregates. Based on that observation, we investigated the involvement
of autophagy. Through a combination of stable autophagy reporter cells and immunoreactivity for LC3 and p62 in
neuronal cells with either α-syn overexpression or treatment of human α-syn preformed fibrils (PFF), we observed that
Drp1 inhibition abolished autophagic impairment induced by α-syn. Consistent with its role in improving autophagy
function, Drp1 inhibition reduced exosome release and spread of α-syn pathology from neurons to neurons and from
microglia to neurons. In summary, this study highlights new insights that Drp1 inhibition confers neuroprotection
through both mitochondrial and autophagy-lysosomal pathways, further strengthening the therapeutic potential of
targeting Drp1.
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Parkinson’s disease (PD) is a complex and multifactorial
disorder involving both genetic mutations and environ-
mental factors [28]. Since the identification of the first
mutation in SNCA [50], the gene encoding α-synuclein
(α-syn), the list of additional mutations linked to PD has
expanded rapidly and become rather complex [28, 29, 53].
To date, the most investigated PD-linked gene is SNCA.© The Author(s). 2019 Open Access This artic
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triplications of SNCA have been identified in familial
PD [3, 34, 38, 50, 61, 73]. The discovery of increasing
the gene dosage of SNCA by two to three fold can also
cause PD [61] signifies that elevated wild-type (WT) α-syn
alone is sufficient to cause the disease. α-syn is promin-
ently present in Lewy bodies, which are intra-neuronal
proteins aggregates commonly observed in PD [64]. Al-
though mutation in this gene is rare, the SNCA locus has
been demonstrated to have genome-wide significant asso-
ciation with PD development [39]. Genome-wide associ-
ation studies (GWAS) have identified SNCA as a major
gene associated with sporadic PD [26, 46, 59]. The factle is distributed under the terms of the Creative Commons Attribution 4.0
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makes it a significant and attractive protein to investigate
pathogenic mechanisms and therapeutic target for this
neurological disorder. Neurotoxic mechanisms associated
with α-syn have therefore been at the forefront of the PD
research and have greatly contributed to the current un-
derstanding of the disease pathology.
α-syn has been demonstrated to induce neurotoxicity
through multiple but non-mutually exclusive mecha-
nisms [7, 17, 22, 28], including impairment in mitochon-
drial and autophagy-lysosomal function resulting in
protein aggregation, mitochondrial impairment, oxidative
stress and exosome release – all of which are the topics of
interest in the present study. Relevant to this study we re-
cently published data demonstrating that by using the small
molecule Mitochondrial Division Inhibitor-1 (mdivi-1), a
putative inhibitor of the mitochondrial fission Dynamic-
Related Protein-1 (Drp1), we were able to reduce neuro-
pathology induced by α-syn-A53T in rats [4]. However,
some critical questions remained from that study. First,
mdivi-1 was used to block Drp1 function [4]. Although this
inhibitor has been widely reported to produce effects con-
sistent with blocking mitochondrial fission and GTPase
function of Drp1 [42, 63], questions have been raised
whether this inhibitor blocks Drp1 function [6]. Second, α-
syn-A53T mutation was used to model PD. Given that this
missense mutation is rare and responsible for a very small
fraction of PD cases, the significance of that study in rela-
tion to sporadic PD needs to be validated in models with
wild-type (WT) human α-syn. Third, to date, Drp1 is com-
monly referred to as a “mitochondrial fission” protein.
However, most of Drp1 resides, not on mitochondria, but
elsewhere in the cell. Indeed, a previous study estimated
that only about 3% of Drp1 is localized to mitochondria
under normal physiological condition [62]. Although under
pathological condition, post-translational modifications
such as phosphorylation of Drp1 at S616, would induce its
translocation to mitochondria, a significant portion most
likely still remains in the cytosol. It is critical to investigate
additional protective mechanisms of this protein. The
present study addresses these three issues and we report
here that blocking Drp1 genetically improved neuropatho-
logical hallmarks associated with mitochondrial dysfunction
and autophagy flux impairment induced by human α-syn-
WT. Consistent with these mechanisms, we observed im-
proved mitochondrial function as well as reduced α-syn ag-
gregation and exosome release when Drp1 was inhibited.
Materials and methods
Cell cultures
Generation of stable and inducible human wild-type α-
synuclein in dopaminergic neuronal cells
Stable cells with inducible α-syn-WT expression were
generated by stably transfecting the rat dopaminergicneuronal cells N27 (1RB3A) [51, 52] (provided by Dr.
Anumantha Kanthasamy, Iowa State University) with an
ecdysone inducible system, the Complete Control Indu-
cible Mammalian Expression System (Stratagene), as we
previously described in details for the PINK1 models [15].
The cDNA of full length human wild-type SNCA was sub-
cloned into the multiple cloning site. Stably transformed
cells were selected and maintained in RPMI containing
10% FBS, G418 (500 μg/ml) and hygromycin (200 μg/ml).
Of note, due to the potential concern that N27 cells in
some laboratories have a mixed population because of ex-
tensive passaging over time, we performed immunocyto-
chemistry and immunoblotting and confirmed that
approximately 91% of our N27 cells have tyrosine hydrox-
ylase (a dopaminergic marker) immunoreactivity (Add-
itional file 1: Figure S1). Quantification was performed by
counting DAPI with or without TH immunoreactivity.
Our initial attempt was to select inducible cells with
high expression of GFP using flow cytometry. However,
due to undetectable GFP intensity (which could occur
for a protein expressed downstream of IRES) [43], we
directly selected cells with high expression of α-syn
using SMARTFLARE human SNCA-Cy3 mRNA probe
(Millipore, SF-1254). This non-toxic probe was taken
up by living cells through endocytosis. Once inside
the cell, it recognizes and binds to human α-syn
mRNA, resulting in fluorescent signal. For sorting,
cells were treated with 20 μM PonA (or ethanol ve-
hicle control) for 24 h and SMARTFLARE probe (200
nM) was added ~ 16 h prior to sorting using FAC-
SAria II. Cells were maintained in RPMI 1640 con-
taining10% FBS, G418 (500 μg/ml) and hygromycin B
(200 μg/ml) (complete medium). The expression of α-
syn upon PonA induction was confirmed using immu-
nostaining and western blot.
Stable autophagy reporter HeLa cells
HeLa cells with stable overexpression of mRFP-GFP-
LC3 were designed to monitor autophagy flux as previ-
ously described [32]. We have successfully used these
cells to measure autophagy flux [9, 10]. These cells were
maintained in DMEM + 10%FBS + G418 (100 μg/ml) +
1% penicillin/streptomycin. Of note, because we needed
to performed immunostaining to identify cell with α-syn
overexpression, we chose to use fixed cells instead of live
cell imaging in this study. Due to the potential concern
that fixation may bring back the quenched GFP signal,
we directly compared the signal intensity of cells with or
without PFA fixation. As seen below Additional file 1:
Figure S2, GFP signal was not affected by fixation; other-
wise, every single cell would have had a green signal –
indicating autophagy flux is functional and the GFP sig-
nal is quenched when autophagosomes fuse with the
acidic environment of the lysosomes.
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Primary cultured mouse microglia were prepared from
post-natal day 0 (P0) newborn C57BL/6 pups as described
[21]. Briefly, meninges-free cortices were isolated and
trypsinized. Cells were cultured in complete DMEM-F12
with 10% FBS and penicillin/streptomycin. Murine mono-
cyte colony stimulating factor (M-CSF, 10 ng/ml, cat.
no.315–02, Peprotech, CA) was added to the medium 6
days after plating. After 15 days, the cultures were shaken
(4 h; 260 rpm on a rotary shaker) to remove microglia.
SH-SY5Y cells and BV2 cells
Human neuroblastoma SH-SY5Y and immortalized
mouse microglia BV-2 cells were cultured in DMEM con-
taining 10% FBS, penicillin G and streptomycin sulfate.
siRNA-mediated Drp1 knockdown
Pre-designed siRNA against rat dnm1l and human
DNM1L (gene encoding Drp1) were purchased from
Dharmacon Research, Inc. SMARTpool: siGENOME Rat
Dnm1l siRNA was used for the N27 cells and SMART-
pool: siGENOME Human Dnm1l siRNA was for HeLa
cells. Each of this product is a mixture of four individual
siRNA duplexes that target four separate sequences of the
gene to maximize efficiency of gene silencing. To enhance
transfection efficiency, an “in-tube” transfection procedure
[15] was used with the following modifications: Cell sus-
pension (80,000–100,000cells/ml) were mixed with jet-
PRIME™ DNA and siRNA Transfection Reagent (Polyplus-
transfection®SA). For every 500 μL of cell suspension (RPMI
+ 10% FBS), 50 μL of JetPRIME buffer and 2 μL JetPRIME
reagent were used. Cells were plated and left in transfection
medium overnight, then media was changed the following
day. Gene silencing efficiency was confirmed using western
blot, with 10 nM of siRNA achieving 75–90% knockdown
compared to scrambled control (siGENOME Non-
Targeting siRNA Control Pools, Cat# D-001206, Dharma-
con Inc) after 48 h.
Preparation of human α-syn pre-formed fibrils (PFF)
α-syn monomers were obtained from the Michael J. Fox
Foundation and the generation of PFF was performed
according to the accompanying protocol (https://www.
michaeljfox.org/files/accelerate/models/PFF%20Protocol
%202017b.pdf). Briefly, the frozen aliquot was thawed on
ice, centrifuged at 15,000×g for 10 min at 4 °C with a
SORVALL legend micro 21R centrifuge (Thermo Scien-
tific). Protein concentration was determined using BCA
assay (Thermo Scientific Pierce) and the samples were
diluted in sterile PBS to 5 mg/ml in a 1.5 ml Eppendorf
protein low-bind tube. The sample was quickly centri-
fuged and placed in an Eppendorf ThermoMixer C or-
bital shaker (with thermo top on), shaken at 1000 RPM
for seven consecutive days at 37 °C. The stock sampleswere aliquoted and stored at − 80 °C. To assess morph-
ology of PFF, transmission electron microscopy (TEM,
Phillip CM120) was used. To this end, the recombinant
protein was diluted into 1 mg/ml in dPBS and sonicated
using either QSonica XL-2000 at power level 2 for a
total of 30 pulses (1 s each) or Fisher Scientific 120 Sonic
Dismembrator equipped with CL-18 microtip (20%
power) and then transferred to carbon-coated 200-mesh
copper electron microscopy grids separately. Subse-
quently, PFF was negatively stained with 1% uranium
acetate and its morphology was identified by TEM.
PFF treatment in cell cultures
The frozen aliquot of α-syn as described above was
thawed at room temperature, diluted to 0.1 mg/ml using
sterile dPBS (volume 200-400 μl), and sonicated as de-
scribed above. The sonicated solution was diluted to
working concentrations in cell culture media prior to be-
ing used for the following experiments:
1) SH-SY5Y and BV-2 cells were transfected with
siRNA-Drp1(50 nM) or scramble control for 12 h,
followed by PFF (2 μg/ml) treatment for 24 h, and
cultured for additional 36 h after PFF withdrawal.
For mdivi-1 treatment, PFF was added concurrently
with mdivi-1 (20 μM). Conditional media (CM)
were then collected for exosome isolation.
2) Mouse primary microglia were treated with PFF for
24 h in the presence or absence of mdivi-1, and
further cultured for 36 h after PFF withdrawal. To
activate microglia, cells were treated with LPS
(1 μg/ml) for 3 h followed by 15 min of ATP (5
mM) before harvesting. Conditioned media (CM)
were collected for exosome isolation.
3) Exosomes. Cultured cells were maintained in media
containing exosome-depleted FBS (cat# EXO-FBS-
50A-1, SBI System Biosciences). Mouse primary
microglia were treated with PFF for 24 h in the
presence or absence of mdivi-1, and further
cultured for 36 h after PFF withdrawal. To activate
microglia, cells were treated with LPS (1 μg/ml) for
3 h followed by 15 min of ATP (5 mM) before
harvesting. Conditioned media (CM) were collected
for exosome isolation. Cell culture media (20 ml)
from two 100 mm plates of primary microglia was
collected 24 h after PFF removal, centrifuges at
3000×g at room temperature for 15 min to remove
cell debris. Exosomes in the resultant supernatant
was precipitated using ExoQuick-TC PLUS
Exosome Purification Kit (Cat# EQPL10TC-1,
SBI System Biosciences) according to the
manufacturer’s instructions. Exosome pellets were
re-suspended in culture medium for cell treatment.
To visualize exosomes, pellets of exosomes were re-
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carbon-coated 200-mesh copper electron
microscopy grids and incubated for 10 min at room
temperature. Exosomes were then incubated with
2% phosphotungstic acid for 3 min. Micrographs
were observed under a transmission electron
microscope (Phillip CM120).
Cell transfection
Cells were transfected with plasmids (0.3 μg/well for 24-
well plate and 1.5 μg/well for 6-well plate) using either
Lipofectamine™ 3000 (Thermo Fisher Scientific) or jet-
PRIME™ DNA and siRNA Transfection Reagent (Polyplus-
transfection®SA) following the manufacture’s protocol.
Immunofluorescence
Cells were grown on borosilicate cover slips pre-coated
with poly-D-lysine in 24-well plates. Prior to immuno-
staining, cells were fixed with 4% formaldehyde (Thermo
Scientific™ Pierce™, #28906), in warm cell culture media
at 37 °C for 20 min. Please refer to the table in Add-
itional file 1 for a list of primary antibodies and dilutions
used. Corresponding Alexa Fluor®(350, 488, 586, and
633) conjugate secondary antibodies (Molecular Probes)
were used at 1:500–1:1000 dilution. Slides were mounted
using Prolong™ gold anti-fade mount with or without
DAPI (Molecular Probes). Images were captured using
Olympus Fluoview 1200 confocal microscope (with the
exception of live cell imaging, which was Olympus Fluo-
view10i automated confocal laser-scanning microscope).
Immunoblotting
For cytosolic samples, cells were lysed with RIPA buffer
(150mM NaCl,1%(v/v) IGEPAL, 0.5% Sodium Deoxycho-
late, 0.1% SDS, 50mM Tris, pH 8.0) containing 1X Halt
Protease and Phosphatase Inhibitor (Thermo Scientific),
dounced for 20–30 times in a 1mL glass homogenizer and
centrifuged at 16,000×g for 15min at 4 °C. Supernatants
were collected and 30-45 μg of protein per well (depending
on respective antibodies) were separated in SDS-PAGE.
For experiments related to exosome release, cells were
sonicated in RIPA buffer. To measure the amount of exo-
somes release, exosomes were extracted from same
amount of culture medium and immunoblotted for exoso-
mal markers (Alix and Tsg101). To quantify the levels of
α-syn in exosomes, the same amount of protein from exo-
somes (40 μg) were loaded. Proteins were separated by
SDS-PAGE and then transferred onto nitrocellulose mem-
branes. The blots were then incubated overnight at 4 °C
with following primary antibodies: anti-Alix, anti-Tsg101,
and anti-alpha synuclein. Secondary antibodies conjugated
with horseradish peroxidase (HRP) were used, and immu-
noreactivity was visualized with chemiluminescence
(SuperSignal Ultra, Pierce, Rockford, IL,USA). Proteinbands were analyzed and quantified using Scion Image
system (Scion Corporation).
Mitochondrial morphology
N27 stable cells were grown on poly-D-lysine-coated glass
coverslips. Mitochondria were visualized with transfected
DsRed-Mito as we previously described [15] and images
were captured using Olympus Fluoview 1200 confocal
microscope. Mitochondrial morphology was quantified
blinded using Image J [15]. More than 500 clearly identifi-
able mitochondria from randomly selected 30–50 cells per
experiment were measured in four independent experi-
ments. Roundness: 4 × ([Area])/(π × [Major axis]2). Aspect
ratio is a measurement of major / minor axes [15], using
ImageJ’, (https://imagej.nih.gov/ij/). Both of these values
approach 1 as the particle becomes circular.
Mitochondrial membrane potential (ΔΨm)
ΔΨm in N27 was quantified using 50 nM tetramethylrho-
damine methyl ester (TMRM) as previously described
[15]. As a positive control, cells were treated with 20 μM
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone
(FCCP) to collapse ΔΨm. Fluorescent signal was analyzed
by BD Accuri C6 flow cytometer using FL-2 channel.
Reactive oxygen species (ROS) quantification
Cellular ROS was measured using the superoxide indica-
tor dihydroethidium (DHE, Invitrogen) as described
[55]. Briefly, N27 stable cells grown in 24-well plates
were treated with 10 μM DHE in cell culture medium
and incubated for 20 min at 37 °C. The dye was then
washed, cells were trypsinized, and analyzed using flow
cytometry (BD Accuri C6),. As a positive control, cells
were treated with 30 μM H2O2.
Mitochondrial ROS was assessed using MitoSOX red
(M36008, Molecular Probes). N27 stable cells were
grown in 96-well plate and incubated with 2.5 μM of
MitoSOX working solution (in HBSS) at 37 °C for 20
min. Cells were then washed three times with PBS and
fluorescent intensity was measured using a plate reader
(Biotek Synergy H1 Hybrid Multi-Mode Reader) at Ex/
Em 510/595. After which cells were washed twice with
PBS, incubated with DAPI (5 μg/ml) in the dark at room
temperature for 10 min and washes three times before
the DAPI signal was quantified using the Biotek plate
reader (Ex/Em 358/461). Treatment of 50 nM rotenone,
a mitochondrial complex I inhibitor, for 48 h was used
as a positive control to generate mitochondrial ROS.
Mitochondrial respiration
Mitochondrial function in live cells was assessed using the
Seahorse XFe96 Extracellular Flux Analyzer (Seahorse Bio-
sciences Inc). Cells were grown in the Seahorse 96-well
plates overnight for attachment. On the following day, cell
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serum free assay medium (Dulbecco’s Modified Eagle’s
Medium with - 5.5mM Glucose, 1.0mM Sodium Pyruvate,
4mM Glutamine, 2mM HEPES, pH 7.4), incubated in a
37 °C non-CO2 incubator for at least 30min before being
loaded into the analyzer. Mitochondrial respiration was
measured using the Mito-Stress Test (Seahorse Biosciences
Inc) as instructed by the manufacturer. Oligomycin (1 μg/
ml), FCCP (0.5 μM), rotenone (1 μM) and antimycin A
(1 μM) were sequentially added to cells to determine mito-
chondrial respiration. Each oxygen consumption rate data
point refers to the mean rates during each measurement
cycle, which consists of a mixing time of 30s followed by a
data acquisition period of 3min. Three data points were ac-
quired after each injection, and four data points were re-
corded for basal respiration [69]. For normalization, cells
were fixed with 4% PFA, followed by incubation of DAPI
(80 μl of 5 μg/ml in PBS) for 10min. The plate was then
washed 3 time with PBS, and fluorescent signal DAPI for
was quantified at Ex/Em 358/461 nm using the Biotak Syn-
ergy H1 Hybrid Reader.
To calculate total ATP production rate, which, in cell, is
the sum of ATP generated by oxidative phosphorylation and
glycolysis. Proton production, measured as the extracellular
acidification rate in the XFe96 analyzer, also include two
sources: (1) pyruvate to lactate− conversion directly through
glycolysis, and (2) CO2 to HCO3
− reaction in the TCA cycle
indirectly from pyruvate feeding into the process. In addition,
the amount of ATP produced per glucose through glycolysis
and oxidative pathways differs significantly. Therefore, in-
stead of directly comparing extracellular acidification rate
(ECAR) with oxygen consumption rate (OCR) as cell glyco-
lytic/metabolic index, we adapted the calculation methods by
Mookerjee and colleagues [44] to compare the ATP pro-
duced by both pathways.
Total ATP production ¼ ATPglyc þ ATP oxð Þ
ATPox ¼ OCR coupledð Þ x 2P=Ooxphos
 
þ OCRmito x 2P=OTCA½  ðP=O defined as mol
of ATP produced by per mol of oxygen atomÞ
ATPglyc ¼ PPRglyc x ATP=lactate
 
þ OCRmito x 2P=Oglyc
 
Glycolytic rateð Þ PPRglyc ¼ ECARtot=buffering power 
OCRmito x max H
þ=O2 x 10pHpK1
 
= 1þ 10pHpK1   
OCRmito ¼ OCRtot  OCRR=A
Quantification of autophagic vesicles
The analysis of autophagy flux in stable HeLa cells ex-
pressing mRFP-GFP-LC3 was performed as described[8]. Green vesicles represent autophagosomes because
when the autophagosome fuses with the lysosomes, the
pH sensitive GFP signal is quenched by the acidic envir-
onment in the lysosomes. Red vesicles are made up of
both autophagosomes and autolysosomes. The number
of autolysosomes was obtained by subtracting the num-
ber of green vesicles from that of the red vesicles. For
analysis, cells were imaged with an Olympus Fluoview
with 60x time objective, autophagosomes and autolyso-
somes from at least 50 cells per treatment group were
counted using ImageJ. For N27 cells, autophagy blockage
was assessed through quantification of LC3-mcherry
puncta together with the immunostained p62 puncta.
Proteinase K digestion
To determine the formation of aggregation in cells, Pro-
teinase K digestion was performed. Freshly fixed cul-
tured cells were washed 3X5min with PBS, then treated
with Proteinase K (~ 0.34 U/ml, Sigma P4850). The
plates were then incubated in the dark at room
temperature for 10 min with gentle shaking, followed by
3X5min washes with PBS and subsequently immuno-
stained for α-syn.
Phospho4E-BP-1 immunoblotting
N27 stable cells were transfected with Drp1 siRNA (10
nM) or scramble control (10 nM) overnight and then in-
duced with PonA for 48 h. Overnight rapamycin treat-
ment (1 μM) was used as a control to inhibit mTOR.
Cells were then harvested for western blotting. The
phosphorylated form of mTOR substrate protein 4E-BP1
was probed using Phospho-4E-BP1 (Thr37/46) (236B4)
Rabbit monoclonal antibody (Cell Signaling Technology,
catalogue #2855), 1:500 dilution, and subsequently
probed with goat anti-rabbit IgG HRP conjugate (Bio-
rad) with 1:5000 dilution.
Statistics
Data represent mean ± SEM. For normally distributed
data, differences between means were analyzed using
one-way ANOVA, followed by Newman-Keuls post hoc
testing for pairwise comparison. The null hypothesis was
rejected when the p value < 0.05.
Results
Drp1 inhibition reduces mitochondrial fragmentation
induced by α-syn in rat dopaminergic neuronal cells
To have an experimental model stably overexpressing a
neurotoxic protein such as α-syn, we used an ecdysone
inducible system to overexpress human wild-type α-syn
in the rat dopaminergic neuron cells N27. The ecdysone
inducible approach provides a tight regulation of the
transgene expression, a strategy that we previously used
successfully to generate inducible cells overexpressing
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the cell population with inducible α-syn expression was
selected by fluorescence activated cell sorting (FACS)
after using a Cy3-mRNA probe specific to human α-syn
mRNA. The inducible expression of α-syn was then fur-
ther characterized using immunocytochemistry and
western blotting (Fig. 1, Additional file 1: Figure S3).
Based on our time-course and dose-response studies, a
treatment of 20 μM of Ponasterone A (PonA, an ecdys-
one analog) for 48 h was chosen to induce α-syn expres-
sion - unless otherwise specified in some specific
experiments.
After the successful generation of these stable α-syn
dopaminergic neuronal cells, we first assessed the impact
of α-syn on mitochondrial morphology. Using DsRed-
Mito transfection to visualize mitochondria, we observed
that these organelles were fragmented in cells with α-syn
overexpression (Fig. 1a). However, stable cells with
empty vector control displayed tubular mitochondria.
This observation appeared to be mediated by Drp1 be-
cause increased levels of this fission protein were ob-
served at the mitochondrial and total levels, as
demonstrated using immunocytochemistry (Fig. 1a) and
immunoblotting (Fig. 1b), respectively. To investigate
the effects of Drp1 inhibition on mitochondrial fragmen-
tation induced by α-syn, we used complementary genetic
and pharmacological approaches to reduce Drp1 func-
tion as we previously described [4, 15, 56]. First, we
transfected cells with siRNA-Drp1, which achieved ap-
proximately 70–80% of Drp1 knockdown efficiency
(Additional file 1: Figure S4). Second, we transfected
cells using the dominant negative mutant Drp1-K38A.
Third, the small molecule mitochondrial division
inhibitor-1 (mdivi-1). As demonstrated morphologically
(Fig. 1c-e) and quantitatively (Fig. 1f), all three strategies
blocked mitochondrial fragmentation induced by α-syn.
Of note, siRNA-Drp1 did not appear to reduce the levels
of α-syn as compared to the group that received scram-
bled siRNA. To quantify more objectively the levels of
α-syn in these two groups of cells, we performed im-
munoblotting and confirmed that the levels of α-syn be-
tween cells transfected with scramble-siRNA and Drp1-
siRNA were not statistically different (6.72 ± 0.31 vs
6.16 ± 1.76, data represent mean ± SEM from 3 inde-
pendent experiments using actin as a loading control).
Drp1 inhibition improves mitochondrial function and
reduces oxidative stress induced by α-syn
Based on the observation that inducible α-syn-WT im-
paired mitochondrial morphology (Fig. 1), we asked
whether mitochondrial function was also impaired in
this cell model, and if so, would blocking Drp1 attenuate
such dysfunction. To this end, we evaluated multiple
mitochondrial function parameters. First, we measuredmitochondrial membrane potential (ΔΨm), which is
established by the electrochemical gradient from redox
reactions generated by the mitochondrial electron trans-
port chain (ETC). This gradient is responsible for driving
ATP production, and therefore a decrease in ΔΨm is in-
dicative of mitochondrial dysfunction. Using flow cytom-
etry, we quantified fluorescent intensity of
tetramethylrhodamine (TMRM) taken up by mitochon-
dria in N27 cells. After 48 h of induction, α-syn signifi-
cantly reduced ΔΨm. Drp1 inhibition, either mediated by
gene silencing (Fig. 2a) or the small inhibitor mdivi-1
(Fig. 2b), completely prevented this deficit. Second, to
directly measure mitochondrial function, we quantified
mitochondrial respiration using the Seahorse XFe96
Extracellular Flux Analyzer (Fig. 2c). We calculated ATP
production rate by either oxidative phosphorylation or
glycolysis. Figure 2d & e show that α-syn specifically re-
duced mitochondrial respiration but not glycolysis.
siRNA-Drp1 or mdivi-1 attenuated this deficit. Next, we
evaluated mitochondrial spare respiratory capacity
(SRC), which represents the ability of mitochondria to
provide substrate supply and electron transport in re-
sponse to an increase in energy demand. α-syn sup-
pressed SRC and siRNA-Drp1 (Fig. 2f) and mdivi-1 (Fig.
2g) preserved SRC despite the presence of α-syn.
An impairment in mitochondrial function invariably
would lead to free radical production such as reactive
oxygen species (ROS). To determine whether such ROS
production would originate from mitochondria resulting
in a higher total cellular ROS, we quantified MitoSOX
Red and Dihydroethidium (DHE) signals to detect mito-
chondrial superoxide and cellular ROS levels, respect-
ively (Fig. 2h-k). Rotenone, a complex I inhibitor, was
used as a positive control to generate ROS from the
ETC blockade. Consistent with its inhibitory effect on
mitochondrial function, α-syn increased ROS levels, an
adverse effect that was blunted by Drp1 inhibition (Fig.
2h-k). Taken together, these mitochondrial studies sup-
port the negative effects of α-syn on the mitochondrial
ETC and that blocking Drp1 is protective.
Drp1 inhibition attenuates autophagic blockade and
protein aggregation in dopaminergic N27 neuronal cells
with inducible α-syn
Protein aggregation is a common pathological feature of
α-syn. In our cell model proteinase-K resistant α-syn ag-
gregates were detectable 2 days after gene induction
(Fig. 3a, arrows). Knocking down Drp1 with siRNA dras-
tically reduced such protein aggregation (Fig. 3b, c). This
genetic approach provided data consistent with our pre-
vious publication where α-syn-A53T accumulation in
rats was significantly reduced by mdivi-1 [4]. Because
autophagy is a primary pathway by which α-syn is de-
graded [67], one possible mechanism by which Drp1
Fig. 1 Drp1 inhibition reduces mitochondrial fragmentation induced by α-syn in rat dopaminergic neuronal cells. a Stable rat dopaminergic N27
cells with ecdysone-inducible system containing human wild type SNCA were transfected with DsRed-Mito overnight, treated with 20 μM PonA
for 48 h to induce α-syn expression, followed by immunostaining for α-syn (gray) and Drp1 (green). Representative images show the effects of α-
syn on mitochondrial morphology and Drp1 colocalization with mitochondria. b Total levels of α-syn and Drp1 in stable cells expressing empty
vector control or SNCA after 48 h of 20 μM PonA treatment were assessed using immunoblotting. c N27 cells were co-transfected with DsRed-
Mito and rat siRNA-Drp1 or scramble control overnight, then induced with PonA for 48 h. Representative images showing siRNA-Drp1, but not
scramble control, attenuated mitochondrial fragmentation induced by α-syn. d As a complementary genetic approach, N27 cells were co-
transfected with the dominant-negative mutation Drp1-K38A (HA- tagged) and DsRed-Mito, then induced with PonA for 48 h before
immunostained for HA and α-syn. Representative images showing mitochondrial morphology in Drp1-K38A expression (arrows pointing to the
characteristic Drp1 puncta formation) cells versus α-syn overexpression alone. e N27 cells were transfected with DsRed-Mito, and induced with
PonA plus mdivi-1 (10 μM) or vehicle control (DMSO) for 48 h. Scale bars: 20 μm. Imaging data from c-e were quantified for mitochondrial
morphology using Image J and summarized quantitatively in f. Both the values of “roundness” and “aspect ratio” approach 1 as the particle
becomes circular. Data represents mean ± SEM, analyzed by one-way ANOVA (n = 4 or 5 independent experiments with > 500 mitochondria
/group quantified for each experiment), followed by Newman-Keuls post hoc test. *p < 0.05
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autophagic flux. Since LC3-II is selectively associated
with autophagosomes, LC3-II or LC3-decorated vesicles
has been widely used to indicate autophagosome levels
or contents in cells [33]. The levels of p62 as a selectiveautophagy substrates inversely correlate with autophagic
flux [5]. To test the hypothesis Drp1 inhibition would at-
tenuate autophagic impairment induced by α-syn, we
quantified the levels of LC3-II and p62 levels in the N27
cells with inducible α-syn expression. To achieve this
Fig. 2 Drp1 inhibition improves mitochondrial function and reduces oxidative stress induced by α-syn. Drp1 inhibition was performed as
described in Fig. 1 and the expression of α-syn was induced with 20 μM PonA for 48 h before the following experiments were performed: a & b
Mitochondrial membrane potential (ΔΨm) was assessed using TMRM (50 nM), and fluorescent intensity was analyzed using flow cytometry. The
uncoupler agent carbonyl cyanide 4- (trifluoromethoxy) phenylhydrazone (FCCP, 20 μM) was used as positive control to collapse ΔΨm to
establish the threshold. Signal intensity (AU, arbitrary unit) was expressed as % above this threshold. c-g Mitochondrial respiration and glycolysis
in live cells were assessed by measuring oxygen consumption rate and extracellular acidification rate using the XFe96 Extracellular Flux Analyzer.
Sequential injections of oligomycin (to inhibit oxygen consumption mediated by ATP synthase), FCCP (an uncoupler to induce maximal OCR),
Rotenone/Antimycin (to inhibit complex I and III, respectively). Spare Respiratory Capacity was calculated as % = (Maximal Respiration) / (Basal
Respiration) × 100. α-syn overexpression reduced ATP production rate through oxidative phosphorylation, but not through glycolysis (d & e) as
well as impaired spare respiratory capacity (f & g). Drp1 knockdown and mdivi-1 conferred protection. MitoSox red dye (h & i) and dihydroethidium
(DHE, j & k) were used to measure mitochondrial and total cellular ROS, respectively, and signal intensity was quantified by plate reading and flow
cytometry respectively. Data represent the mean ± SEM, one-way ANOVA (n = 4), followed by Newman-Keuls post hoc test. *p < 0.05 ** p ≤ 0.02,
*** p < 0.001
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Fig. 3 Drp1 inhibition attenuates autophagic blockade and protein aggregation in dopaminergic N27 neuronal cells with inducible α-syn. a & b
Stable N27 cells were transfected with siRNA-Drp1 or scramble control for 24 h, then induced with PonA for an additional 48 h, fixed and
immediately incubated with Proteinase-K (PK) for digestion. Drp1 and α-syn were then immunostained (arrows pointing to the characteristic PK
resistant α-syn puncta) c PK resistant α-syn punta were quantified using Image J. d & e Stable N27cells were co-transfected with LC3-cherry plus
either siRNA-Drp1 or scramble control for 24 h, then induced with PonA for an additional 48 h. Cells were then immunostained for α-syn and p62. f
LC3 and p62 punta were quantified using Image J. Data represents mean ± SEM, n = 3–4 independent experiments with 20–30 cells per treatment
group were counted in each experiment, analyzed by one-way ANOVA, followed by Newman-Keuls post hoc test. *p < 0.05. *p < 0.05 Scale bar: 10 μm
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Drp1 or scramble control for 24 h and then induced α-
syn for 48 h, followed by immunoblotting for p62and
LC3I/II. The levels of p62 were significantly elevated
after α-syn induction. siRNA-Drp1, but not scramble-
siRNA, significantly reduced the levels of p62 in cells
with α-syn overexpression but did not change the base-
line levels of p62 in cells without α-syn overexpression
(Additional file 1: Figure S5). Of note, endogenous levels
of LC3 in N27 cells were too low to be detected reliably.
Therefore, we co-transfected N27 cells with LC3-cherry
plasmid to facilitate quantification of LC3 puncta in
these neuronal cells. As seen in Fig. 3d-f, α-syn signifi-
cantly increased the number of LC3 puncta, supporting
accumulation of autophagosomes. Using immunocyto-
chemistry to simultaneously detect p62 in these cells, we
also observed an increase in p62 puncta levels, indicating
a blockade of autophagy. (Fig. 3d-f). These data suggest
that autophagy-lysosomal pathway is compromised in α-
syn-expressing cells, consistent with previous reports
[16, 23]. The accumulation of these autophagic proteins,
however, was significantly attenuated by siRNA-Drp1
(Fig. 3d-f), but not scramble siRNA control, suggestingthat Drp1 inhibition restores autophagy-lysosomal activ-
ity or autophagic flux.
Drp1 inhibition prevents autophagy flux impairment
induced by α-syn in autophagy reporter HeLa cells
As illustrated in our schematic diagram, autophagy plays
a critical role in removing misfolded proteins (Fig. 4a).
An impairment in autophagy has been well-established
to result in accumulation of protein aggregation [57].
We recently demonstrated that pharmacological block-
ing of Drp1 dramatically reduced α-syn aggregates in ni-
gral DA neurons of rats overexpressing α-syn [4].
However, it was not determined whether such protective
effect was mediated through autophagy. Although data
presented in Fig. 3d-f support the role of Drp1 in au-
tophagy, to more directly monitor autophagy flux in the
present study, we utilized the autophagy reporter HeLa
cells with stable overexpression of mRFP-GFP-LC3
(Fig. 4b). These cells were designed to monitor au-
tophagy flux [32]. mRFP-GFP-LC3 vesicle analysis al-
lows us to monitor autophagosome synthesis and
autophagosome-lysosome fusion by labelling autopha-
gosomes (green and red) and autolysosomes (red),
Fig. 4 Drp1 inhibition prevents autophagy flux impairment induced by α-syn in the autophagy reporter cells. a Schematic diagram illustrating
the autophagy flux pathway and b the construct used to create the mRFP-GFP-LC3 stable reporter HeLa cells. With this cell model,
autophagosomes appear yellow due to the colocalization RFP and GFP signals. Red signal indicates the flux is functional because the green
signal is quenched by the acidic environment of the lysosome, which fuses with autophagosome. c These stable Hela cells were co-transfected
with human α-syn-wild type plasmid and siRNA-Drp1 or with scramble (scr) control. Representative images of cells transfected with empty vector
(EV) control, α-syn, α-syn plus scramble siRNA, and α-syn plus siRNA-Drp1 were captured using confocal microscopy. d The numbers of
autophagosomes (green vesicles) and autolysosomes (red vesicles minus green vesicles) were quantified using ImageJ. e & f As a complementary
genetic approach, these reporter cells were co-transfected with plasmids expressing α-syn plus either Drp1- K38A (HA-tagged) or empty vector
control. After 48 h, cells were fixed and immunostained with anti-α-syn and anti-HA antibodies and subsequently quantified for autophagosomes
and autolysosomes. g Hela cells were transfected with α-syn as described above and treated with the putative Drp1 inhibitor mdivi-1 (10 μM) or
vehicle control 24 h later. Next day, cells were fixed and immunostained for α-syn. h. Quantitative analysis of autophagosomes and
autolysosomes using Image J. i Cells were transfected with either scramble or siRNA-Drp1 for 24 h before the addition of α-syn pre-formed fibrils
(PFF, 8 μg/well) for 48 h, changed media for 24 h and then fixed and immunostained for α-syn. j Quantitative analysis of autophagosomes,
autolysosomes and α-syn puncta was performed using image J. All data represent mean ± SEM, n = 3–4 independent experiment with ~ 30 cells
analyzed per group, using one-way ANOVA followed by the Newman--Keuls post hoc test. *p < 0.05. Scale bar: 20 μm
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Previously, α-syn was shown to impair autophagic
flux with increased autophagosome accumulation and
reduced autophagosome-lysosome fusion [23]. To in-
vestigate whether blocking Drp1 would improve au-
tophagy flux impaired by α-syn, we co-transfectedthese autophagy reporter cells with wild type human
α-syn in the presence or absence of siRNA-Drp1 or
siRNA-scramble control (Fig. 4c). After 48 h, cells
were immunostained for α-syn and the number of
autophagosomes and autolysosomes were quantified
in these immunoreactive cells in a blinded manner.
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but not scramble control, significantly attenuated
autophagosome accumulation and enhanced autolyso-
somal levels in the cells with α-syn overexpression,
indicating that Drp1 knockdown alleviates autophagic
impairment induced by α-syn. Using another genetic
approach to reduce Drp1 function, we transfected
cells with the mutant Drp1-K38A dominant negative
(Fig. 4e & f). In cells with Drp1-K38A expression as
evidenced by immunostaining of the HA-tag, autophagy
flux was significantly improved despite the co-transfection
of α-syn. As a comparison to genetic approaches, we also
assessed the effects of the small molecule mitochondrial
division inhibitor-1 (mdivi-1) in this study. Figure 4g & h
demonstrate that mdivi-1 also protected against α-syn-
induced autophagy blockade.
Human α-syn preformed fibrils (PFF) has been used in re-
cent years to induce the release of exosomes and the spread
of α-syn from one cell to another in vitro [24, 40, 65] and
in vivo [40]. Small seeds of PFF generated from recombinant
α-syn can be endocytosed by neurons where it recruits en-
dogenous α-syn to form phosphorylated and insoluble ag-
gregates [65]. We obtained α-syn monomers from the
Michael J. FOX Foundation and generated PFF according to
the accompanying protocol. With transmission electron mi-
croscopy (TEM), we confirmed the morphology and size of
PFF and its sonicated form (Additional file 1: Figure S6).
Using the autophagy reporter HeLa cells, we confirmed that
PFF blocked autophagy flux and siRNA-Drp1 attenuated
this impairment (Fig. 4i & j). Furthermore, this treatment
also reduced α-syn protein aggregation (Fig. 4i & j). To-
gether, in a cell model designed to monitor autophagy flux,
our genetic and pharmacological data provide strong evi-
dence that blocking Drp1 alleviates the negative impact of
α-syn on autophagy flux and therefore supporting a novel
protective mechanism of Drp1 inhibition.
Drp1 inhibition attenuates lysosomal impairment and
inhibits mTOR activity
To investigate how and at what stage of autophagy flux
Drp1 inhibition has an impact on, we transfected the au-
tophagy reporter mRFP-GFP-LC3 HeLa cells (Fig. 5a) with
siRNA-Drp1 or scramble control and then treated them
with chloroquine to block lysosomal function, as evi-
denced by a reduction in autolysosomes (Fig. 5b) and an
increase in autophagosomes (Fig. 5c). These alterations
were attenuated by Drp1 inhibition, suggesting a partial
improvement in lysosomal function, however, a direct
measure of lysosome function is needed to confirm this ef-
fect. Interestingly, the number of autophagosomes
remained relatively high in the cells with higher levels of
autolysosomal activity under Drp1 inhibition (Fig. 5c).
This result suggests that Drp1 inhibition might also pro-
mote the formation of autophagosomes. Therefore, intheory, Drp1 inhibition enhances autophagy flux by in-
creasing both the levels of autophagosomes and the func-
tion of lysosomes. To gain additional mechanistic insights
into the observed higher autophagosome levels, we trans-
fected stable N27 cells were with siRNA-Drp1, followed
by α-syn induction for 2 days and then cells were collected
for immunoblotting to assess mTOR activity (which in-
hibits autophagy) by quantifying the levels of phosphor-
4E-BP1 (Fig. 5d&e), which is a downstream substrate of
mTOR. Consistent with previous study, we observed α-
syn activated mTOR (Fig. 5d&e), and strikingly, knocking
down Drp1 inhibited mTOR activity to an equivalent ex-
tent as rapamycin, an mTOR inhibitor. Together, our pre-
liminary data provide a highly novel evidence that Drp1
inhibition increases autophagy flux by a combination of
increasing the formation of autophagosomes and perhaps
the function of lysosomes as well.
Blocking Drp1 reduces exosome release from SH-SY5Y
cells treated with PFF
Autophagosome can either fuse with lysosomes for deg-
radation or fuse with the endosomal multivesicular bod-
ies (MVBs) to form amphisome [60]. Upon fusion of
amphisome or MVBs with the plasma membrane, exo-
somes are secreted as extracellular vesicles [71]. Im-
paired autophagy flux, therefore, would increase the
release of exosomes. Based on the observations de-
scribed above demonstrating that blocking Drp-1 en-
hanced autophagy flux and inhibited α-syn aggregation,
we hypothesized that Drp1 inhibition may also reduce
exosome release. Because N27 cells release undetectable
levels of exosomes, we used SH-SY5Y to test this hy-
pothesis. First, we performed Drp1 knockdown and then
treated cells with PFF, followed by collecting conditioned
medium and extracted exosomal fraction (EF), which was
then used to treat another group of SH-SY5Y cells (see
schematic diagram in Fig. 6a). Images obtained from
transmission electron microscopy (TEM) revealed that EF
was enriched with micro-vesicles 50–100 nm (Fig. 6b),
which is consistent with the size of exosomes. Strikingly,
similar to the donor cells treated with PFF (Fig. 6c), the re-
cipient cells treated with EF for 4 days also showed strong
signal for α-syn (Fig. 6c). These results indicate that exo-
somes released from PFF treated donor neurons can be
taken up by the recipient neuronal cells to serve as seeds
to induce aggregation of α–syn. However, in cells with
Drp1-knockdown, the appearance of α–syn in the donor
and recipient cells was much reduced (Fig. 6c). Next,
using a similar experimental paradigm (Fig. 6d), we ob-
served that mdivi-1 also attenuated α–syn aggregation in
the donor and recipient cells (Fig. 6e). To quantify the ob-
served alterations more objectively, equal volume of con-
ditioned medium from each group of cells was probed for
the content of exosomes (Fig. 6f) and the same amount of
Fig. 5 Drp1 inhibition improves lysosomal function and inhibits mTOR activity. a - c Hela autophagy reporter cells were transfected with siRNA-
Drp1 or scramble control and then treated with 25 μM chloroquine (CQ) overnight (16 h) a Cells were immunostained with an Drp1 antibody.
Images were captured and autophagosome/ autolysosome quantification b & c was performed using ImageJ as described above. Data represent
mean ± SEM (n = 3 independent experiments). One-Way ANOVA with Newman–Keuls post-hoc analysis * p < 0.05; compared to the vehicle
control group. d & e Stable N27 cells were transfected with siRNA-Drp1, and then induced with PonA (20 μM) next day to induce α-syn
expression. 48 h after, cells were collected and lysed for western blot analysis d. Phospho-4E-BP1 was probed and normalized to β-actin e Data
represent mean ± SEM (n = 4–5 independent experiments), One-way ANOVA followed by Newman–Keuls post-hoc testing * p < 0.05; compared
to the control group
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levels of α–syn (Fig. 6g). Our data strongly indicate that
not only did Drp1 inhibition reduce exosome release in-
duced by PFF, but also less α–syn content was present in
the released exosomes. These results are consistent with
the mechanism of improving autophagy flux by Drp1
inhibition.
Drp1 inhibition reduces protein aggregation induced by
exosomes from PFF-treated microglia
To investigate whether microglia would release exo-
somes and if so, whether blocking Drp1 would attenuate
such a release from microglia, we treated primary mouse
microglia with LPS, PFF or both in the presence or ab-
sence of mdivi-1 (Fig. 7a). Subsequently, conditioned
media were collected for exosome isolation. The amount
of exosome released from primary microglia was quanti-
fied using immunoblotting (Fig. 7b). It is evident that
these treatments increased the release of exosomes from
microglia and when combined with LPS, PFF further en-
hanced the release of exosomes and their content of α-
syn (Fig. 7c). To assess the spread of α-syn from micro-
glia to neuronal cells, exosomal fraction from LPS + PFF
treated microglia was incubated with SH-SY5Y cells for
4 days to allow internalization to occur. As demon-
strated in Fig. 7d, confocal images revealed α-synaggregation in these recipient neuronal cells and mdivi-1
reduced such aggregation. Due to the low level of effi-
ciency of knocking down Drp1 in primary microglia,
only the small molecule mdivi-1 was used. To further
corroborate the role of Drp1 in microglial exosome re-
lease, we turned to the mouse microglial cell line BV2.
These cells were transfected with siRNA-Drp1 or scram-
ble control, followed by the PFF and LPS treatment as il-
lustrated in Fig. 7e. Immunoblotting confirmed that
Drp1 inhibition reduced the content of α-syn in micro-
glial exosomes (Fig. 7f), reduced exosome release from
microglia (Fig. 7g) and reduce the spread of α-syn to
neuronal cells (Fig. 7h). In combination, results from pri-
mary microglia and BV2 cells indicate that microglia are
capable of releasing α-syn-containing exosomes, thereby
spreading α-syn to neurons. Blocking Drp1 significantly
reduces these pathological processes.
Discussion
Mitochondrial dysfunction and impaired autophagy flux
represent two major pathogenic mechanisms in PD.
After the discovery of 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) as the chemical causing parkinson-
ism [35], mitochondrial dysfunction mediated by
blockade of the electron transport chain has been quite
well-investigated in PD. However, a more recent
Fig. 6 Blocking Drp1 reduces exosomal release from SH-SY5Y cells treated with PFF. a Experimental design: SH-SY5Y cells were transfected with
siRNA-Drp1 or scramble control for 12 h, followed by PFF (2 μg/ml) treatment for 24 h, and cultured for an additional 36 h after PFF withdrawal.
Conditioned media (CM) were then collected for exosomal isolation and the remaining cells were immunostained for α-syn (red). Isolated
exosomes were added to a second group of SH-SY5Y cells for 24 h and then immunostained for α-syn. b TEM confirmed micro-vesicles in the
exosomal fraction to be consistent with the size of exosomes. Scale bar: 100 nm. c Immunofluorescence of α-syn in two groups of SH-SY5Y cells
as described in a: Group 1 donor cells were treated with PFF and Group 2 recipient cells were treated with the exosomal fraction extracted
obtained from the Group 1 cells. Control 1 received no PFF treatment, only vehicle control. Control 2 received no siRNA. Scale bar: 10 μm. d
Schematic diagram illustrating SH-SY5Y cells treated with mdivi-1 and e immunofluorescence of α-syn (red) of the Group 1 donor cells and
Group 2 recipient cells as described in c. Scale bar: 10 μm. f Equal volume of CM was loaded into each well for immunoblotting, and the amount
of exosomes were quantified using Alix and Tsg101 as markers for exosomes. Data represent the mean ± SEM, (n = 6). g To quantify the amount
of α-syn release, equal amount of exosomes were used for immunoblotting, and α-syn was probed against the loading control Alix. Data
represent the mean ± SEM, (n = 4), One-way ANOVA followed by Newman–Keuls post-hoc testing.* p < 0.05
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fusion and fission, not only for PD but also other neuro-
degenerative diseases [2, 31, 66]. It is now recognized
that a balance in mitochondrial fusion and fission iscritical to neuronal function and viability. Mitochondrial
fusion requires the coordination of both the inner
(IMM) and the outer (OMM) mitochondrial mem-
branes. The OMM proteins Mitofusin 1 & 2 (Mfn1/2)
Fig. 7 Drp1 inhibition reduces protein aggregation induced by exosomes from PFF-treated microglia. a Experimental scheme: In the presence or
absence of mdivi-1, mouse primary microglia were treated with PFF for 24 h, and further cultured for 36 h after PFF withdrawal. To activate
microglia, cells were treated with LPS (1 μg/mL) for 3 h followed by 15 min of ATP (5 mM) before harvesting. Conditioned media (CM) were
collected for exosome isolation, and cells were lysed for western blot quantification: b. Equal volume of CM were loaded into each well and
quantified for exosome levels using Alix and Tsg101 as markers. Data represent the mean ± SEM, (n = 3). c Equal amount of exosomes were
loaded into each well to quantify for α-syn content. Data represent the mean ± SEM, (n = 4). d SH-SY5Y cells were incubated with extracted
exosomes from PFF + LPS treated microglia for 4 days and immunostained for α-syn. Scale bar: 20 μm. e Experimental scheme: BV-2 microglia
were transfected with siRNA-Drp1 prior to PFF treatment, and cells were treated with PFF (2 μg/ml) for 24 h and further cultured for 36 h after
PFF withdraw, during which time cell were activated with LPS (1 μg/ml) and ATP (5 mM) for 3 h and 15min, correspondingly. Then the
conditional media were collected for exosome isolation, and cells were lysed for western blot quantification. f Same amount of EF was loaded for
western blot analysis confirming the reduction of α-syn in exosomes via Drp1 silencing. Data represent the mean ± SEM, (n = 4). g Equal volume
of CM were loaded into each well for western blot quantification of exosome markers Alix and Tsg101, and Drp1 silencing reduced exosome
release from BV2 cells. Data represent the mean ± SEM, (n = 6). h SH-SY5Y cells treated with EF from BV2 cells were fixed after 24 h and stained
for α-syn. Representative ICC images showing Drp1 knockdown in donor cells (BV2) significantly reduced α-syn aggregation formation in recipient
cells (SH-SY5Y). Scale bar: 20 μm Data were analyzed using one-way ANOVA followed by Newman–Keuls post-hoc testing. * p < 0.05
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join the membrane. Mitochondrial fission is governed by
a separate set of proteins: Mitochondrial Fission Factor
(Mff), Fission-1 (Fis1), as well as Mitochondrial Dynam-
ics Proteins of 49 and 51 kDa (MiD49 and MiD51, re-
spectively) are anchored to the OMM where they recruit
cytosolic Dynamin-related protein-1 (Drp1), which then
oligomerizes and forms a ring-like structure around the
mitochondria to constrict and split them [36, 49]. Be-
cause Drp1 can bind to multiple downstream fission
proteins to sever mitochondria, it has earned the reputa-
tion as a master regulator of mitochondrial fission. How-
ever, as demonstrated in the present study, in addition
to this well-established function, Drp1 has a novel role
in autophagy.
Autophagy plays a critical role in removing misfolded
proteins, including α-syn [14, 37, 67]. Therefore, impair-
ment in autophagy leads to accumulation of α-syn, which
further exacerbating the blockade of autophagy as demon-
strated cell culture and animal models [4, 11, 19, 68, 72],
thus creating a bidirectional positive feedback loop of
neurotoxicity [70]. Strikingly, recent data from other la-
boratories and ours show that blocking Drp1 is capable of
reducing protein aggregation. Reddy and colleagues, for
example, reported than crossing Drp1+/− mice with either
the AβPP (Tg2576) or the Tau P301L transgenic mouse
models of (AD) reduced accumulation of toxic proteins in
these animals [30, 41]. We recently demonstrated that
pharmacological blocking of Drp1 dramatically reduced α-
syn aggregates in nigral DA neurons of rats overexpressing
α-synclein-A53T [4]. Together, these results suggest that
one possible mechanism by which blocking Drp1 reduces
protein aggregation is through an improvement in au-
tophagic function.
Given the well-established function of Drp1 in mito-
chondrial fission and its potential role in autophagy, the
present study evaluated the protective effects of Drp1 in-
hibition mediated through these two mechanisms. Using
primarily genetic approaches to inhibit Drp1, we report
here that reduced Drp1 function conferred protection
against α-syn induced impairment in both mitochondria
and autophagy. In stable dopaminergic neuronal cells with
inducible expression of α-syn, reducing Drp1 function
genetically (Drp1 knockdown and overexpression of
Drp1-dominant negative) and pharmacologically (mdivi-1
treatment) attenuated the negative impacts of α-syn on
mitochondrial morphology and function (membrane po-
tential, reactive oxygen species, respiration and spare re-
spiratory capacity (SRC). A reduction in SRC leads to
energy crisis when energy demand exceeds the supply
ability of mitochondria. Indeed, SRC has been considered
as a major factor that defines the survival of the neuron
[13]. Importantly, Drp1 inhibition drastically reduced pro-
teinase K-resistant α-syn aggregates as demonstratedusing complementary approaches of reducing Drp1 func-
tion in multiple cell models with overexpressing human
wild-type α-syn or the treatment of recombinant α-syn
(PFF). Consistent with these observations of protein clear-
ance, we demonstrated that Drp1 inhibition abolished au-
tophagic impairment induced by α-syn in multiple cell
models. Furthermore, we assessed mTOR activity by
quantifying the levels of its substrate, phosphor-4E-BP1,
using immunoblotting of N27 cells overexpressing α-syn
with siRNA-Drp1 or scramble control. These results dem-
onstrate that reducing Drp1 function blocks mTOR activ-
ity and thereby increasing autophagy flux. In combination,
our data indicate that that Drp1 inhibition confers protec-
tion against α-syn by both improving mitochondrial func-
tion and autophagy flux.
Blockade of the mitochondrial electron transport chain
and autophagy flux has been shown to induce the spread
of α-syn inter-cellularly. For example, exposure of enteric
neurons to rotenone, a mitochondrial complex I inhibitor,
promotes the release of α-syn, which is subsequently taken
up by and form aggregates in the recipient neurons [47].
Emerging evidence indicates that α-syn can spread inter-
cellularly through exosome release, primarily because of
its ability to impair mitochondria and autophagy [1, 25].
Exosomes are small extracellular vesicles with a typical
size of 40–100 nm. Because these vesicles carry cargos
such as mRNA and proteins, they could play a role in the
spread of misfolded proteins such as α-syn [12]. It has
been demonstrated that impaired autophagy induces
exosome-mediated α-syn spread to other neurons [1],
forming aggregates and inducing death in the receiving
cell [18, 27]. As demonstrated in this study, in addition to
neurons, microglia are capable of releasing exosomes. Our
data also indicate that when activated by LPS, microglia
release drastically more exosomes. The role of activated
microglia in causing neuroinflammation by releasing mol-
ecules such as TNF-α, IL-1β and IL-6 has been well-
documented and proposed to be involved in PD pathogen-
esis. Relevant to this study, LPS has been reported to in-
duce mitochondrial fission in microglia leading to
neuroinflammation. Using primary microglia [45] and the
BV2 murine microglial cells [48], two independent studies
show that LPS induces mitochondrial fragmentation and
neuroinflammation via a Drp1-dependent mechanism.
Blocking Drp1 using shDrp1 and mdivi-1 reduces LPS-
induced release of pro-inflammatory molecules. In
addition to microglia, astrocytes are capable of causing
neuroinflammation [58] - although to a lesser extent than
microglia. In primary mouse astrocytes and the human
U373 astrocytes, manganese (Mn) reduces oxidative phos-
phorylation, increases mitochondrial fragmentation and
neuroinflammation - especially in the presence of supple-
mented aggregated α-syn [58]. The mitochondrial targeted
antioxidant mito-apocynin was demonstrated to be highly
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cytes [58], suggesting impaired mitochondria as the cause
of neuroinflammation. Together, these studies indicate
that enhanced mitochondrial fission in microglia and as-
trocytes are linked to their production of proinflammatory
molecules. It is most likely that the reduction of exosome
release observed in this study was mediated through
mechanisms related to improved mitochondrial function,
reduced neuroinflammation and improved autophagy
when Drp1 was inhibited.
Conclusions
Mitochondrial dysfunction, impaired autophagy flux,
oxidative stress and α-syn pathology (aggregation and
spread) have all been proposed to play a dominant
pathogenic role in PD. Blocking Drp1 function as a po-
tential therapeutic strategy has gained interest in recent
years for neurodegenerative diseases. We have reported
that blocking Drp1 is neuroprotective in cell [15] and
animal models of PD [4, 56]. A complementary approach
using a peptide known as P110 to block the binding of
Drp1 to Fis1 has also been shown to be protective in the
MPTP models [20, 54]. However, all these previous stud-
ies focused on the mitochondrial fission pathway. Using
models of α-syn, which is relevant to familial and spor-
adic PD, the present study provides the following novel
observations: First, in addition to improving mitochon-
drial morphology and function, blocking Drp1 improved
autophagy flux. Second, Drp1 inhibition reduced protein
aggregation and spread from one cell to another via exo-
somes and non-cell autonomous mechanism. Together,
these discoveries highlight new insights that Drp1 inhib-
ition confers neuroprotection through both mitochon-
drial and autophagy-lysosomal pathways, further
strengthening the therapeutic potential of targeting
Drp1. The discovery that blocking Drp1 in microglia
confers protection in neurons suggest that Drp1 should
also be considered to be reduced in glial cells, not just in
the affected neuronal population.
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